rheumatoid arthritis
BMS backs rheumatoid arthritis prevention trial
March 27, 2015Sales and Marketing BMS, Bristol-Myers Squibb, Orencia, RA, abatacept, rheumatoid arthritis
Bristol-Myers Squibb is funding a £3 million trial of Orencia as a preventative treatment for rheumatoid arthritis. The study will …
AbbVie highlights treatment adherence
June 12, 2014Sales and Marketing ALIGN, AbbVie, Abbott, Crohn’s disease, TNF, ankylosing spondylitis, psoriasis, psoriatic arthritis, rheumatoid arthritis, treatment, ulcerative colitis
Patients with inflammatory diseases tend to be better at following their treatment regimes with TNF inhibitors rather than other medicines, …
Janssen abandons Simponi application
May 23, 2014Sales and Marketing Europe, Janssen, RA, Simponi, rheumatoid arthritis
Janssen Biologics has withdrawn its application to add an intravenous (IV) form to the marketing authorisation of veteran rheumatoid arthritis …
Pfizer’s Xeljanz rejected in Europe
April 28, 2013Sales and Marketing CHMP, Humira, Pfizer, RA, Xeljanz, rheumatoid arthritis
Pfizer has suffered a major setback with the rejection of its new arthritis drug in Europe.The EMA’s medicines committee the …
MedImmune signs China deal
September 11, 2012Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, China, MedImmune, WuXi, emerging markets, rheumatoid arthritis
MedImmune has sealed a joint venture with Shanghai-based WuXi AppTec to develop a novel biologic for autoimmune and inflammatory diseases …
Pfizer’s RA drug on course for approval
May 10, 2012Sales and Marketing Humira, JAK inhibitor, Pfizer, RA, rheumatoid arthritis, tofacitinib
An FDA advisory committee has recommended for approval Pfizer’s new rheumatoid arthritis treatment tofacitinib.The Arthritis Advisory Committee voted 8-2 to …
NICE says no to BMS for second-line Orencia
August 25, 2011Sales and Marketing BMS, NICE, Orencia, rheumatoid arthritis
In final draft guidance NICE has not recommended the use of Bristol-Myers Squibb’s arthritis drug Orencia after other drugs have …
Sanofi eyes phase III move for sarilumab in rheumatoid arthritis
July 13, 2011Research and Development Regeneron, Sanofi, ankylosing spondylitis, research and development news, rheumatoid arthritis, sarilumab
Sanofi is poised to move sarilumab into phase III trials for rheumatoid arthritis after the monoclonal antibody showed positive results …
Deaths reported in Pfizer arthritis trial
April 26, 2011Research and Development, Sales and Marketing Pfizer, rheumatoid arthritis, tofacitinib
Four deaths have been reported in a late-stage study of Pfizer’s arthritis drug tofacitinib. Three of the deaths are thought …
Phase III boost for Pfizer’s oral arthritis drug
April 18, 2011Research and Development, Sales and Marketing Pfizer, rheumatoid arthritis, tofacitinib
Pfizer’s rheumatoid arthritis treatment tofacitinib has induced clinical remission of the disease according to one-year data from a phase III …
Abbott wins $1.7bn Humira case
February 24, 2011Sales and Marketing Abbott, Abbott Laboratories, Centocor, Johnson and Johnson, Remicade, Simponi, TNF, golimumab, infliximab, rheumatoid arthritis
Abbott has been saved from paying Johnson & Johnson $1.7 billion after a US appeals court quashed a patent dispute …
Streaming Well and National Rheumatoid Arthritis Society Team up to Promote Awareness
October 15, 2010Medical Communications NRAS, National Rheumatoid Arthritis Society, rheumatoid arthritis, streaming well
LONDON UK – Patient education video producer and distributor
Solid results for AstraZeneca’s oral RA drug
September 23, 2010Research and Development AstraZeneca, Rigel, fostamatinib, rheumatoid arthritis
AstraZeneca’s new oral treatment for rheumatoid arthritis has produced solid results in a phase II trial. Fostamatinib is the first …
NICE updates guidance for arthritis treatments
August 26, 2010Sales and Marketing NICE, Roche, rheumatoid arthritis
Five new drugs for rheumatoid arthritis have been given the thumbs up by NICE as second line treatment. Roche’s MabThera, …
NICE re-thinks arthritis guidance
June 25, 2010Sales and Marketing Enbrel, Humira, MabThera, NICE, Orencia, Remicade, TNF, rheumatoid arthritis
NICE has approved five rheumatoid arthritis treatments in certain circumstances after treatment with a tumour necrosis factor inhibitor has failed. …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
